Research Analysts’ Recent Ratings Changes for Maplight Therapeutics (MPLT)

A number of research firms have changed their ratings and price targets for Maplight Therapeutics (NASDAQ: MPLT):

• 6/24/2026 – Maplight Therapeutics is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $46.00 price target on the stock.
• 6/24/2026 – Maplight Therapeutics was upgraded by Raymond James Financial, Inc. to “strong-buy”.
• 6/23/2026 – Maplight Therapeutics had its price target lowered by Craig Hallum from $43.00 to $40.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by Benchmark Co..
• 6/22/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 6/22/2026 – Maplight Therapeutics had its price target raised by Needham & Company LLC from $37.00 to $42.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Maplight Therapeutics had its price target raised by Stifel Nicolaus from $28.00 to $36.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 5/26/2026 – Maplight Therapeutics is now covered by UBS Group AG. They set a “buy” rating and a $48.00 price target on the stock.
• 5/26/2026 – Maplight Therapeutics was upgraded by UBS Group AG to “strong-buy”.
• 5/21/2026 – Maplight Therapeutics is now covered by Craig Hallum. They set a “buy” rating and a $43.00 price target on the stock.
• 5/14/2026 – Maplight Therapeutics was upgraded by Lifesci Capital to “strong-buy”.

Insider Buying and Selling

In other Maplight Therapeutics news, CFO Vishwas Setia sold 10,564 shares of the firm’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $28.24, for a total value of $298,327.36. Following the completion of the transaction, the chief financial officer directly owned 356,256 shares of the company’s stock, valued at $10,060,669.44. This trade represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher A. Kroeger sold 118,235 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $27.19, for a total value of $3,214,809.65. Following the completion of the sale, the chief executive officer directly owned 1,394,094 shares in the company, valued at approximately $37,905,415.86. The trade was a 7.82% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 495,244 shares of company stock worth $14,079,461. Insiders own 3.80% of the company’s stock.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.